About Fermiscan Limited

Fermiscan is working to develop a world-first innovative test for the detection of breast cancer using hair. The breakthrough technology that underpins the Fermiscan™ Test is the discovery by an Australian scientist that breast cancer can potentially be detected by synchrotron x-ray diffraction of hair. The test is non-invasive and suitable for women from as early as 20 years of age. It may provide early detection of breast cancer thus assist in early treatment. Early detection benefits range from increased survival, increased treatment options and improved quality of life. The Fermiscan™ Test is in trial and not yet available commercially.

Investor Relations

The Investor relations section will keep current and potential investors informed with the latest shareholder information.

Below is the Fermiscan Holdings Limited share price, in addition the shareholder section will allow you to access your unit holding information. The ASX announcements list the current and historical reports and our latest results can be found in the Reports section where you can access both Annual Reports and Investor Reports. In the Corporate governance section Fermiscan has provided documents that outline Fermiscan's corporate governance policies which were in place as at March 2007.


Click for market data